20
Cat No. | Product Name | Synonyms | Targets |
---|---|---|---|
T79813 | Raf inhibitor 3 | Raf | |
Raf inhibitor 3 (Example 30), a potent inhibitor of both B-Raf and C-Raf, exhibits IC50 values below 15 nM. It is applicable in cancer research studies [1]. | |||
T41003 | KG5 | Raf , FLT , PDGFR , c-Kit | |
KG5 is a dual allosteric inhibitor of PDGFRβ and B-Raf with a Kd of 520 nM and 300 nM for PDGFRβ and PDGFRα. KG5 inhibits FLT3, KIT, and c-Raf with anticancer and antiangiogenic activities. | |||
T6525 | GW 5074 | GW5074,Raf1 Kinase Inhibitor I | Apoptosis , Raf |
GW 5074 (Raf1 Kinase Inhibitor I)(IC50=9 nM) is an effective and specific c-Raf inhibitor. It has no effect on the activities of JNK1/2/3, MEK1, MKK6/7, CDK1/2, c-Src, p38 MAP, VEGFR2 or c-Fms. | |||
T0093L | Sorafenib | Bay 43-9006 | Apoptosis , Raf , VEGFR , FLT , Ferroptosis , PDGFR , c-Kit , Autophagy |
Sorafenib (Bay 43-9006) is a multikinase inhibitor that inhibits Raf-1, B-Raf, VEGFR2, VEGFR3, VEGFR4, PDGFRβ, FLT3, c-Kit, and others (IC50=6/22/90/15/20/20/57/58 nM) with oral activity. Sorafenib has antitumor activity... | |||
T0093 | Sorafenib tosylate | Bay 43-9006 | Apoptosis , Raf , VEGFR , FLT , Ferroptosis , PDGFR , c-Kit , Autophagy |
Sorafenib tosylate (Bay 43-9006) is a potent multikinase inhibitor (IC50s: 6/20/22 nM for Raf-1/VEGFR-3/B-Raf). | |||
T6296 | RAF265 | CHIR-265 | Apoptosis , Raf , VEGFR , Autophagy |
RAF265 (CHIR-265) (CHIR-265) is a potent selective inhibitor of C-Raf/B-Raf/B-Raf V600E with IC50 of 3-60 nM, and exhibits potent inhibition on VEGFR2 phosphorylation with EC50 of 30 nM. Phase 2. | |||
T16909 | Sorafenib-d3 | Sorafenib (D3),Bay 43-9006 (D3) | Raf , VEGFR |
Sorafenib-d3 (Bay 43-9006 (D3)) is a deuterium-labeled Sorafenib which is a multikinase inhibitor(IC50s: 6 nM, 20 nM, and 22 nM for Raf-1, B-Raf, and VEGFR-3, respectively). | |||
T9585 | GNE-9815 | 3-(2-cyanopropan-2-yl)-N-[2-fluoro-4-methyl-5-(7-methyl-8-oxo-7,8-dihydropyrido[2,3-d]pyridazin-3-yl)phenyl]benzamide | Raf |
GNE-9815 (3-(2-cyanopropan-2-yl)-N-[2-fluoro-4-methyl-5-(7-methyl-8-oxo-7,8-dihydropyrido[2,3-d]pyridazin-3-yl)phenyl]benzamide) is a high kinase-selective inhibitor of RAF and targets KRAS-mutant cancers through combina... | |||
T1792L | Regorafenib monohydrate | Raf , VEGFR , c-RET , PDGFR , c-Kit , Autophagy | |
Regorafenib Monohydrate is a novel oral multikinase inhibitor with IC50 values of 13, 4.2, 46, 22, 7, 1.5, 2.5, 28, 19 nM for VEGFR1, murine VEGFR2, murine VEGFR3, PDGFR-β, KIT, RET, RAF-1, B-RAF and B-RAF(V600E) respect... | |||
T10157 | Regorafénib N-oxyde (M2) | Raf , VEGFR , c-RET , PDGFR , c-Kit , Drug Metabolite | |
Regorafénib N-oxyde M2 is an active metabolite of Regorafenib. Regorafenib is a multi-target inhibitor for VEGFR1/2/3, PDGFRβ, RET, Kit, and Raf-1 (IC50s: 13/4.2/46, 1.5, 22, 7, and 2.5 nM). | |||
T9638 | CCT241161 | Raf | |
CCT241161 is an orally active pan-RAF inhibitor, with IC50 values of 3, 6, 10, 15, and 30 nM for LCK, CRAF, SRC, V600E-BRAF, and BRAF, respectively. It displays significant activity against BRAF and NRAS mutant melanomas... | |||
T2617 | SNS-314 Mesylate | SNS-314 | Aurora Kinase |
SNS-314 Mesylate (SNS-314) is an effective and specific Aurora A/B/C inhibitor (IC50: 9/31/3 nM). It is less inhibition of Trk A/B, Fms, Flt4, c-Raf, Axl, and DDR2. | |||
T8402 | Regorafenib Hydrochloride | BAY73-4506 hydrochloride | Raf , VEGFR , c-RET , PDGFR , Autophagy |
Regorafenib Hydrochloride (BAY73-4506 hydrochloride) is a new oral multikinase inhibitor of angiogenic, stromal and oncogenic receptor tyrosine kinases with potent preclinical antitumor activity | |||
T2624 | OSI-930 | OSI 930 | Apoptosis , c-Fms , Raf , VEGFR , FLT , CSF-1R , Src , c-Kit |
OSI-930, an orally active inhibitor of c-Kit and the vascular endothelial growth factor receptor-2 (VEGFR-2), targets cancer cell proliferation and blood vessel growth (angiogenesis) in tumors. | |||
T61935 | B-Raf IN 9 | ||
B-Raf IN 9 (compound 8b) is an effective B-Raf inhibitor (IC50=24.79 nM). B-Raf IN 9 blocks cell cycle at G2/M phase and induces apoptosis. B-Raf IN 9 showed potent anti-tumor activity on human prostate cancer PC-3 cells... | |||
T12976 | Sorafenib-d4 | Sorafenib (D4),Bay 43-9006 (D4) | Others |
Sorafenib D4 is the deuterium labeled Sorafenib. Sorafenib is an inhibitor of multikinase (Raf-1, B-Raf, and VEGFR-3 IC50s of 6 nM, 20 nM, and 22 nM, respectively). | |||
T60727 | B-Raf IN 8 | ||
B-Raf IN 8 (compound 7g) is a potent inhibitor of B-Raf (IC 50 = 70.65 nM). B-Raf IN 8 shows antitumor activity which has IC 50 values of 9.78, 13.78, 18.52 and 29.85 μM against hepatocellular carcinoma (HEPG-2), colon ... | |||
T60933 | B-Raf IN 7 | ||
B-Raf IN 7 (compound 6a) is a potent inhibitor of B-Raf with an IC 50 of 110.23 nM. B-Raf IN 7 has antitumor activity against colon carcinoma cells(HCT-116), mammary gland cells(MCF-7), hepatocellular carcinoma cells(HEP... | |||
T72659 | KRAS inhibitor-3 | ||
KRAS inhibitor-3, an efficacious inhibitor of both wild-type (WT) and oncogenic KRAS mutations, exhibits high-affinity binding (K D: 0.28 μM for KRAS WT, 0.63 μM for KRAS G12C, 0.37 μM for KRAS G12D, and 0.74 μM for KRAS... | |||
T64090 | Regorafenib mesylate | ||
Regorafenib (BAY 73-4506) mesylate is an orally active multi-target receptor tyrosine kinase inhibitor that inhibits VEGFR1/2/3 (IC50=13/4.2/46 nM), PDGFRβ (IC50: 22 nM), Kit (IC50: 7 nM), RET (IC50: 1.5 nM) and Raf-1 (I... |